Trials that use: Exact / Clopper-Pearson binomial
New to this method? Read the tutorial →
1,265 results
- NOM-ERAIndependent statistical analysis of Non-Operative Management and Early Response Assessment in Rectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03904043).
- Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ: Complete Statistical AnalysisIndependent statistical analysis of Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Non-Invasive Cooling of Fat Cells: Complete Statistical AnalysisIndependent statistical analysis of Non-Invasive Cooling of Fat Cells: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00762437).
- NOTESIndependent statistical analysis of Natural Orifice Transgastric Endoscopic (NOTES) Transgastric Diagnostic Peritoneoscopy With Laparoscopic Assistance: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Novel Antiaging Regenerative Skin Care Regimen Containing Human Platelet Extract (HPE): Complete Statistical AnalysisIndependent statistical analysis of Novel Antiaging Regenerative Skin Care Regimen Containing Human Platelet Extract (HPE): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Novel Portable Diagnostic Device for Automatic Detection of Relative Afferent Pupillary Defect: Complete Statistical AnalysisIndependent statistical analysis of Novel Portable Diagnostic Device for Automatic Detection of Relative Afferent Pupillary Defect: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- NRRIndependent statistical analysis of Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- NTRKIndependent statistical analysis of A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours: Complete Statistical AnalysisIndependent statistical analysis of NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- NUCALA® Special Drug Use Investigation (EGPA, Long-term): Complete Statistical AnalysisIndependent statistical analysis of NUCALA® Special Drug Use Investigation (EGPA, Long-term): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03557060).
- NUDGE-EHRIndependent statistical analysis of NUDGE-EHR Replication Trial at Mass General Brigham: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05538065).
- Nurse Education in Subjects With Psoriasis Undergoing Treatment With Adalimumab: Complete Statistical AnalysisIndependent statistical analysis of Nurse Education in Subjects With Psoriasis Undergoing Treatment With Adalimumab: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01435265).
- OASISIndependent statistical analysis of Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04720664).
- Obatoclax for Systemic Mastocytosis: Complete Statistical AnalysisIndependent statistical analysis of Obatoclax for Systemic Mastocytosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00918931).
- Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma: Complete Statistical AnalysisIndependent statistical analysis of Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Observational Examination of Thermoregulation in Total Joint Arthroplasty: Complete Statistical AnalysisIndependent statistical analysis of Observational Examination of Thermoregulation in Total Joint Arthroplasty: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02225743).
- Observational Study on Hypothyroidism in Young Children Following Iodine Contrast Exposure: Complete Statistical AnalysisIndependent statistical analysis of Observational Study on Hypothyroidism in Young Children Following Iodine Contrast Exposure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Observational Trial With Enbrel: Complete Statistical AnalysisIndependent statistical analysis of Observational Trial With Enbrel: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00488475).
- Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin’s Lymphoma (B-NHL): Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval,…
- Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy: Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01258933).
- Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL): Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL: Complete Statistical AnalysisIndependent statistical analysis of Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03570476).
- Olaparib in Adults With Recurrent/Metastatic Ewing’s Sarcoma: Complete Statistical AnalysisIndependent statistical analysis of Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01583543).
- Omalizumab in the Treatment of Peanut Allergy: Complete Statistical AnalysisIndependent statistical analysis of Omalizumab in the Treatment of Peanut Allergy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00949078).
- ON TARGET DMIndependent statistical analysis of Comparison of Type 2 Diabetes Pharmacotherapy Regimens: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05073692).
- ONC201 in Adults With Recurrent H3 K27M-mutant Glioma: Complete Statistical AnalysisIndependent statistical analysis of ONC201 in Adults With Recurrent H3 K27M-mutant Glioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03295396).
- ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study: Complete Statistical AnalysisIndependent statistical analysis of One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00580788).
- One-Year Trial of Oral Ziprasidone in Bipolar Patients With Metabolic Syndrome: Complete Statistical AnalysisIndependent statistical analysis of One-Year Trial of Oral Ziprasidone in Bipolar Patients With Metabolic Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- ONTAKIndependent statistical analysis of A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML): Complete Statistical AnalysisIndependent statistical analysis of Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Onyx ONE ClearIndependent statistical analysis of A Single Arm Trial With Resolute Onyx in ONE-Month DAPT for High-Bleeding Risk Patients Who Are Considered One-Month Clear (Onyx ONE Clear): primary endpoint results, effect estimate with…
- OPALINEIndependent statistical analysis of OPALINE : A Study Of Morbidity And Mortality At 2 Years: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known: Complete Statistical AnalysisIndependent statistical analysis of Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known: primary endpoint results, effect estimate with…
- Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only: Complete Statistical AnalysisIndependent statistical analysis of Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy: Complete Statistical AnalysisIndependent statistical analysis of Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05459688).
- Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF: Complete Statistical AnalysisIndependent statistical analysis of Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD): Complete Statistical AnalysisIndependent statistical analysis of Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD): primary endpoint results, effect estimate with confidence interval, sample-size…
- Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study: Complete Statistical AnalysisIndependent statistical analysis of Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study: primary endpoint results, effect estimate with confidence interval,…
- Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa: Complete Statistical AnalysisIndependent statistical analysis of Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02904902).
- Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) – Tuberculosis (TB) Co-infection: Complete Statistical AnalysisIndependent statistical analysis of Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy: Complete Statistical AnalysisIndependent statistical analysis of Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213): Complete Statistical AnalysisIndependent statistical analysis of Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Operative vs Non-Operative Management of Acute Appendicitis and Acute Cholecystitis in COVID-19 Positive Patients: Complete Statistical AnalysisIndependent statistical analysis of Operative vs Non-Operative Management of Acute Appendicitis and Acute Cholecystitis in COVID-19 Positive Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Opioid Free and Therapy Minimized Advantages Using HANA Table for Total Hip Arthroplasty: Complete Statistical AnalysisIndependent statistical analysis of Opioid Free and Therapy Minimized Advantages Using HANA Table for Total Hip Arthroplasty: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Opioid Use Disorder in the Emergency Department: CTN 0069: Complete Statistical AnalysisIndependent statistical analysis of Opioid Use Disorder in the Emergency Department: CTN 0069: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03023930).
- Optic-to-Audio Device in a Pediatric Cohort With CLN3-related Conditions or Low Vision: Complete Statistical AnalysisIndependent statistical analysis of Optic-to-Audio Device in a Pediatric Cohort With CLN3-related Conditions or Low Vision: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…